Clinical Trials Logo

Chronic Kidney Disease Stage 3 clinical trials

View clinical trials related to Chronic Kidney Disease Stage 3.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04172103 Completed - Acute Kidney Injury Clinical Trials

The Association Between the Duration of Acute Kidney Injury and New-onset Chronic Kidney Disease After Cardiac or Thoracic Aortic Surgery

Start date: November 19, 2019
Phase:
Study type: Observational

The investigators aimed to evaluate the association between the duration and stage of acute kidney injury (AKI) and the development of chronic kidney disease during postoperative three years in patients undergoing cardiac or thoracic aortic surgery.

NCT ID: NCT04012957 Completed - Anemia Clinical Trials

Desidustat in the Treatment of Anemia in CKD

DREAM-ND
Start date: July 20, 2019
Phase: Phase 3
Study type: Interventional

This is a phase III, multicenter, multi-country, open-label, randomized, active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with CKD who are not on dialysis. The study will be conducted over a period of up to 30 weeks.

NCT ID: NCT03242252 Completed - Clinical trials for Type 2 Diabetes Mellitus

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

SOTA-CKD3
Start date: August 16, 2017
Phase: Phase 3
Study type: Interventional

Primary Objective: To demonstrate the superiority of Sotagliflozin 200 milligrams (mg) and Sotagliflozin 400 mg versus placebo on HbA1c reduction at 26 Weeks in participants with Type 2 diabetes who have inadequate glycemic control and moderate renal impairment. Secondary Objectives: - To assess the effects of Sotagliflozin 200 mg and 400 mg versus placebo with respect to additional measures of glycemic control, blood pressure, and body weight. - To evaluate the safety of Sotagliflozin 200 mg and 400 mg versus placebo.

NCT ID: NCT01748396 Completed - Clinical trials for Chronic Kidney Disease Stage 3

Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol

Start date: July 2012
Phase: Phase 4
Study type: Interventional

Chronic kidney disease (CKD) is an established risk factor for cardiovascular morbidity and mortality, as shown by common manifestations of left ventricular hypertrophy (LVH) and arterial calcifications in CKD patients. Fibroblast growth factor-23(FGF-23) is a recently identified phosphaturic hormone that has been reported to be associated with the development of secondary hyperparathyroidism, cardiovascular morbidity, mortality, CKD progression. While vitamin D is the mainstay therapy in CKD mineral bone disease (CKD-MBD), increased FGF-23 levels have been reported with vitamin D administration. The purpose of this study was to investigate the effect of calcium carbonate when used in conjunction with calcitriol on FGF-23.